Abstract 4369150: AI-enabled Plaque Phenotype Analysis of Coronary Computed Tomography Angiography Findings in Patients with Nonacute Chest Pain using FFR <sub>CT</sub> : Results from the PRECISE Trial
Abstract
Introduction: Advances in coronary computed tomography angiography (CCTA) have enhanced the possibilities for assessment and quantification of coronary artery disease (CAD). Using data from the CCTA arm of the PRECISE randomized trial (non-acute chest pain needing testing), we examined the extent and diffuseness of coronary plaque burden using novel CCTA-derived metrics. Methods: All stable, symptomatic patients from the PRECISE randomized trial who underwent CCTA for evaluation of suspected CAD and had ≥50% diameter stenosis in at least one vessel were included, N=196. 3-vessel CAD patterns were assessed using FFR CT and AI-enabled quantitative plaque analysis (Heartflow). Nadir FFR CT was defined as total drop in FFR CT across the entire vessel. The FFR CT drop over a stenosis was termed stenosis FFR CT (sFFR CT ). The decrement in FFR CT due to diffuse disease was termed diffuse FFR CT (dFFR CT ) and defined as 1 – nadir FFR CT – sFFR CT . Patients were stratified into four groups (NoHEM, FOC, DIF and FOC+DIF) using cohort medians of 0.10 (sFFR CT ) and 0.13 (dFFR CT ) (Table). The Seattle Angina Questionnaire (SAQ) was used to assess symptoms. Results: No hemodynamic disease (NoHEM), FOC, DIF and FOC+DIF were present in 21.5%, 28.6%, 29.6% and 20.4% of patients respectively. Clinical characteristics were similar between groups (Table). FOC and DIF+FOC had the lowest FFR CT nadir values as well as the highest stenosis FFR CT (both p<0.001). Per-patient total plaque volume (TPV, mm 3 ) was higher in FOC and DIF+FOC compared to NoHEM and DIF (p=0.008; Figure). Per-patient noncalcified plaque volume (NCPV, mm 3 ) followed a similar pattern (p=0.004), although % NCPV did not differ (0.86). Per-patient calcified plaque volume (CPV, mm 3 ) and %CPV did not differ between groups (p=0.12 and 0.86). Conclusion: CCTA allows for a more refined CAD plaque burden categorization by separating the FFR CT losses due to focal stenoses and diffuse CAD. Patients with focal or mixed (focal and diffuse) CAD phenotypes were not distinguishable by clinical characteristics, risk burden or angina severity. However, they exhibited higher plaque volumes, particularly noncalcified plaque, than those with no NoHEM or only diffuse disease. Further studies are necessary to examine the prognostic and therapeutic implications of these findings.
Article Details
Authors (15)
Ruurt Jukema
AUMC, Amsterdam, Netherlands
Pamela Douglas
DUKE UNIVERSITY DUMC, Durham, North Carolina, United States
Maros Ferencik
Nick Curzen
University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Jonathan Weir-McCall
University of Cambridge, Cambridge, United Kingdom
Gregg Stone
Mount Sinai Medical Center, New York City, New York, United States
Campbell Rogers
Heartflow, San Carlos, California, United States
Sarah Mullen
Heartflow, San Carlos, California, United States
Nicholas Ng
Platform for the Accelerated Realization, Analysis, and Discovery of Interface Materials (PARADIM), The Johns Hopkins University, Baltimore, MD, USA.
Benjamin Chow
UNIVERSITY OF OTTAWA HEART INSTITUT, Ottawa, Ontario, Canada
Michelle Kelsey
DUKE UNIVERSITY, Durham, North Carolina, United States
Michael Nanna
Yale School of Medicine, New Haven, Connecticut, United States
Sreekanth Vemulapalli
Division of Cardiology, Duke University School of Medicine, Durham, NC (S.V.).
Daniel Mark
DUKE UNIV MEDICAL CTR, Chapel Hill, North Carolina, United States
Jonathon Leipsic
From Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, NJ (P.G.); Columbia University Medical Center/New York Presbyterian Hospital (A.S., R.T.H., M.B.L.), the Cardiovascular Research Foundation (D.J.C., R.T.H., B.R., M.B.L.), and Weill Cornell Medicine (B.R.), New York, and St. Francis Hospital and Heart Center, Roslyn (D.J.C.) — all in New York; University of Colorado Health, Medical Center of the Rockies, Loveland (J.B.O.); Laval University, Quebec, QC (P.P.), St. Paul’s Hospital, University of British Columbia, Vancouver (P.B., J.L.), and McMaster University, Hamilton, ON (T.S.) — all in Canada; Vanderbilt University Medical Center, Nashville (B.R.L., K.G.); Emory University, Atlanta (V.B.); the Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, Stanford (W.F.F.), VA Palo Alto Health Care System, Palo Alto (W.F.F.), California Pacific Medical Center, San Francisco (D.V.D.), Cedars–Sinai Medical Center, Los Angeles (R.R.M.), and Edwards ...